从争议到信任:加强登革热疫苗安全性报告
本文为评论文章,围绕登革热疫苗(Dengvaxia、Qdenga、TV003/TV005)上市后安全性报告不足展开,指出报告实践不一致、基础设施不足和监管框架薄弱等障碍,并借鉴美国与英国的药物警戒模式提出实时透明报告、标准化数字工具、能力建设与全球数据共享等建议。
要点
- 登革热疫苗在血清阴性者中风险升高,机制可能与抗体依赖增强有关但尚未明确。
- 流行区不良事件报告实践不一致、基础设施不足、监管框架薄弱。
- 作者建议建立实时透明报告系统并加强全球数据共享。
核心结论
- 登革热疫苗安全性报告存在缺陷,作者建议通过实时透明报告、标准化数字工具、能力建设和全球数据共享来完善风险获益评估并重建免疫规划信任。
研究设计与样本
- 本文为评论文章,未报告系统检索范围与样本量。
主要发现
- 登革热疫苗包括Dengvaxia、Qdenga和TV003/TV005(美国国立卫生研究院登革热疫苗),其实施受安全性问题挑战。
- 血清阴性个体中风险升高,推测与抗体依赖增强有关,但确切机制仍在研究中。
- 较新疫苗在效力和安全性上显示前景,但因上市后监测不足,其在多样人群中的真实世界表现仍了解甚少。
- 流行区不良事件报告存在实践不一致、基础设施不足和监管框架薄弱等关键障碍。
临床怎么用
- 作者建议采用标准化数字工具、能力增强和全球数据共享举措以确保互操作性和可及性。
- 作者认为应将先进监测与国际合作相结合,以完善风险获益评估并重建对免疫规划的信任。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dengue fever, driven by four serotypes of the Dengue virus and transmitted by Aedes aegypti, presents a major global health threat, impacting billions in tropical and subtropical regions. Severe cases, such as Dengue Shock Syndrome, result in significant mortality, particularly without prompt intervention, placing immense strain on healthcare systems in resource-limited settings. Dengue vaccines-Dengvaxia, Qdenga, and TV003/TV005 (NIH dengue vaccine) -offer potential for control, yet their implementation has been challenged by safety issues, including heightened risks in seronegative individuals, presumably due to antibody-dependent enhancement, though the precise mechanisms remain under investigation. Although newer vaccines show promise in efficacy and safety, their real-world performance across diverse populations remains poorly understood due to insufficient post-marketing surveillance. This commentary evaluates the deficiencies in adverse event reporting, identifying key obstacles such as inconsistent practices, inadequate infrastructure, and weak regulatory frameworks in endemic areas. Drawing on established pharmacovigilance models from the United States and United Kingdom, we propose real-time, transparent reporting systems to strengthen safety monitoring. Recommendations include standardized digital tools, capacity enhancement, and global data-sharing initiatives to ensure interoperability and accessibility. The erosion of public trust following past vaccine controversies highlights the urgent need for transparency to bolster acceptance and inform policy. By integrating advanced surveillance with international cooperation, these measures can refine risk-benefit assessments, rebuild confidence in immunization programs, and maximize the protective impact of dengue vaccines, ultimately reducing the burden on vulnerable populations worldwide.
引用
- Van Truong L, Thuy LT, Hien LT, et al. From controversy to confidence: Strengthening dengue vaccines safety reporting. Vaccine. 2025. PMID: 40669253. doi:10.1016/j.vaccine.2025.127489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。